Zhenhua Hu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zhenhua Hu has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
Jie Zhou
15 shared publicationsHuilin Zheng
11 shared publicationsFangshen Xu
9 shared publicationsZheng Chen
Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Fourth Affiliated Hospital, School of Medicine, Zhejiang University, Yiwu, Zhejiang, China
9 shared publications- Jie Zhou
Department of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310000, China
7 shared publications Lei Zhang
7 shared publications
Latest Publications
- Open Access
- 10 September 2026
- Published by Springer Nature in Cureus
- Vol. 18 (9)
Early Prognostic Value of the Freiburg Index of Post-Transjugular Intrahepatic Portosystemic Shunt Survival in Patients With Hepatocellular Carcinoma Undergoing Liver Transplantation
Background: The Freiburg Index of Post-Transjugular Intrahepatic Portosystemic Shunt (TIPS) Survival (FIPS) integrates clinically relevant indicators of hepatic and renal function, but its prognostic value in patients with hepatocellular carcinoma (HCC) undergoing liver transplantation (LT) remains unclear. This study aimed to evaluate the association of pre-transplant FIPS with post-transplant overall survival (OS) and HCC recurrence and to compare its prognostic performance with that of the Model for End-Stage Liver Disease (MELD). Methods: Adult liver transplant recipients with HCC registered in the Scientific Registry of Transplant Recipients (SRTR) between January 1, 2010, and December 31, 2018, were included. Overall survival was evaluated using Kaplan-Meier analysis and multivariable Cox regression. Because FIPS did not satisfy the proportional hazards assumption, interval-specific effects were estimated for 0-1, 1-2, and 2-3 years after transplantation. Parallel FIPS- and MELD-based prognostic models were compared using Harrell's C-index, time-dependent area under the curve (AUC), calibration analysis, decision-curve analysis, and five-fold cross-validation. HCC recurrence was evaluated using Fine-Gray competing-risk regression, with death without recurrence treated as a competing event. Results: Patients with high FIPS had consistently lower post-transplant survival than those with low FIPS, with one-, two-, and three-year overall survival rates of 89.5%, 84.7%, and 79.6% versus 93.1%, 88.3%, and 83.8%, respectively. After multivariable adjustment, each one-unit increase in FIPS was significantly associated with higher mortality during the first year after transplantation (hazard ratio (HR): 1.125; 95% confidence interval (CI): 1.069-1.183; P<0.001) and during years 2-3 (HR: 1.112; 95% CI: 1.040-1.190; P=0.002), demonstrating a time-dependent prognostic association. A sensitivity analysis excluding Milan criteria included 13,940 recipients and yielded directionally consistent associations, with significant estimates across all three follow-up intervals. FIPS-based risk prediction showed performance comparable to that of MELD across cross-validated C-index, time-dependent AUC, calibration, and decision-curve analyses. In competing-risk analysis, high FIPS showed a trend toward a higher risk of HCC recurrence (subdistribution hazard ratio (sHR): 1.22; 95% CI: 0.97-1.54; P=0.095). Conclusion: Pre-transplant FIPS captures time-dependent variation in early post-transplant survival among patients with HCC and provides prognostic information comparable to MELD. These findings support the potential use of FIPS as a complementary marker for pre-transplant risk stratification and early post-transplant prognostic assessment. Its relationship with post-transplant HCC recurrence warrants further investigation.
- 10 September 2026
- Published by Springer Nature in Cureus
- Vol. 18 (9)
Open AccessEarly Prognostic Value of the Freiburg Index of Post-Transjugular Intrahepatic Portosystemic Shunt Survival in Patients With Hepatocellular Carcinoma Undergoing Liver Transplantation
Background: The Freiburg Index of Post-Transjugular Intrahepatic Portosystemic Shunt (TIPS) Survival (FIPS) integrates clinically relevant indicators of hepatic and renal function, but its prognostic value in patients with hepatocellular carcinoma (HCC) undergoing liver transplantation (LT) remains unclear. This study aimed to evaluate the association of pre-transplant FIPS with post-transplant overall survival (OS) and HCC recurrence and to compare its prognostic performance with that of the Model for End-Stage Liver Disease (MELD). Methods: Adult liver transplant recipients with HCC registered in the Scientific Registry of Transplant Recipients (SRTR) between January 1, 2010, and December 31, 2018, were included. Overall survival was evaluated using Kaplan-Meier analysis and multivariable Cox regression. Because FIPS did not satisfy the proportional hazards assumption, interval-specific effects were estimated for 0-1, 1-2, and 2-3 years after transplantation. Parallel FIPS- and MELD-based prognostic models were compared using Harrell's C-index, time-dependent area under the curve (AUC), calibration analysis, decision-curve analysis, and five-fold cross-validation. HCC recurrence was evaluated using Fine-Gray competing-risk regression, with death without recurrence treated as a competing event. Results: Patients with high FIPS had consistently lower post-transplant survival than those with low FIPS, with one-, two-, and three-year overall survival rates of 89.5%, 84.7%, and 79.6% versus 93.1%, 88.3%, and 83.8%, respectively. After multivariable adjustment, each one-unit increase in FIPS was significantly associated with higher mortality during the first year after transplantation (hazard ratio (HR): 1.125; 95% confidence interval (CI): 1.069-1.183; P<0.001) and during years 2-3 (HR: 1.112; 95% CI: 1.040-1.190; P=0.002), demonstrating a time-dependent prognostic association. A sensitivity analysis excluding Milan criteria included 13,940 recipients and yielded directionally consistent associations, with significant estimates across all three follow-up intervals. FIPS-based risk prediction showed performance comparable to that of MELD across cross-validated C-index, time-dependent AUC, calibration, and decision-curve analyses. In competing-risk analysis, high FIPS showed a trend toward a higher risk of HCC recurrence (subdistribution hazard ratio (sHR): 1.22; 95% CI: 0.97-1.54; P=0.095). Conclusion: Pre-transplant FIPS captures time-dependent variation in early post-transplant survival among patients with HCC and provides prognostic information comparable to MELD. These findings support the potential use of FIPS as a complementary marker for pre-transplant risk stratification and early post-transplant prognostic assessment. Its relationship with post-transplant HCC recurrence warrants further investigation.
- Open Access
- 8 August 2026
- Published by Elsevier in Materials Today Bio
- Vol. 40
Electroporation-primed cascade nanocatalysis boosts STING-driven chemoimmunotherapy in hepatocellular carcinoma
- 8 August 2026
- Published by Elsevier in Materials Today Bio
- Vol. 40
Open AccessElectroporation-primed cascade nanocatalysis boosts STING-driven chemoimmunotherapy in hepatocellular carcinoma
- 23 January 2026
- Published by Elsevier in Journal of Clinical and Experimental Hepatology
- Vol. 16 (3) , 103473
Machine Perfusion in Liver Transplant from Marginal Donors: Current Practices and Future Directions
- 23 January 2026
- Published by Elsevier in Journal of Clinical and Experimental Hepatology
- Vol. 16 (3) , 103473
Machine Perfusion in Liver Transplant from Marginal Donors: Current Practices and Future Directions
- 10 December 2025
- Published by Springer Nature in Bratislava Medical Journal
- Vol. 127 (1) , 48-60
Advancing Therapeutic Strategies for Pancreatic Cancer: A Review of Surgical, Systemic and Diagnostic Innovations
- 10 December 2025
- Published by Springer Nature in Bratislava Medical Journal
- Vol. 127 (1) , 48-60
Advancing Therapeutic Strategies for Pancreatic Cancer: A Review of Surgical, Systemic and Diagnostic Innovations
- Open Access
- 1 December 2025
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 12, 2989-3009
Construction of 3D Enhanced CT Radiomics-Based Model to Predict Circadian Gene Expression and Prognosis in Hepatocellular Carcinoma
Circadian disruption contributes to hepatocellular carcinoma (HCC) progression. This study aimed to develop a CT-based radiomics model to non-invasively predict circadian rhythm (CR) gene expression profiles for improved prognostic assessment. Mendelian randomization (MR) analysis revealed a significant causal association between CR disorders and the risk of HCC. In Cohort 1 (TCGA database, n = 424), 32 CR-related genes were identified from an initial set of 71 genes. Univariate Cox regression analysis identified 18 prognosis-related genes, and a risk model containing 8 genes was constructed using LASSO and multivariate Cox regression. This model was then validated in Cohort 2 (ICGC database, n = 232). The gene CRTC2 was further validated in vitro. Radiomics features were constructed based on enhanced CT images from Cohort 3 (TCIA database, n = 45) to predict CR risk genes, and the prognostic value of the model was validated in Cohort 4 (The Fourth Affiliated Hospital of Zhejiang University School of Medicine, n = 38). The CR risk gene model stratified patients into high- and low-risk groups with significantly different survival outcomes in both TCGA and ICGC cohorts (TCGA: P < 0.001; ICGC: P = 0.029). The risk score was independently associated with overall survival (HR = 3.582, 95% CI: 2.101–6.107, P < 0.001). Experimental results confirmed that knockdown of CRTC2 significantly inhibited HCC cell proliferation, migration, invasion, and induced apoptosis. The radiomics model achieved an AUC of 0.931 in the training set and 0.760 in the validation set for predicting CR gene expression. Importantly, in the clinical validation cohort, patients with low radiomics scores had significantly longer survival (P = 0.039). Circadian rhythm-related gene expression, implicated in HCC development, can be non-invasively predicted via CT-based radiomics. The proposed model offers promise for prognostic stratification and personalized treatment planning in HCC.
- 1 December 2025
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 12, 2989-3009
Open AccessConstruction of 3D Enhanced CT Radiomics-Based Model to Predict Circadian Gene Expression and Prognosis in Hepatocellular Carcinoma
Circadian disruption contributes to hepatocellular carcinoma (HCC) progression. This study aimed to develop a CT-based radiomics model to non-invasively predict circadian rhythm (CR) gene expression profiles for improved prognostic assessment. Mendelian randomization (MR) analysis revealed a significant causal association between CR disorders and the risk of HCC. In Cohort 1 (TCGA database, n = 424), 32 CR-related genes were identified from an initial set of 71 genes. Univariate Cox regression analysis identified 18 prognosis-related genes, and a risk model containing 8 genes was constructed using LASSO and multivariate Cox regression. This model was then validated in Cohort 2 (ICGC database, n = 232). The gene CRTC2 was further validated in vitro. Radiomics features were constructed based on enhanced CT images from Cohort 3 (TCIA database, n = 45) to predict CR risk genes, and the prognostic value of the model was validated in Cohort 4 (The Fourth Affiliated Hospital of Zhejiang University School of Medicine, n = 38). The CR risk gene model stratified patients into high- and low-risk groups with significantly different survival outcomes in both TCGA and ICGC cohorts (TCGA: P < 0.001; ICGC: P = 0.029). The risk score was independently associated with overall survival (HR = 3.582, 95% CI: 2.101–6.107, P < 0.001). Experimental results confirmed that knockdown of CRTC2 significantly inhibited HCC cell proliferation, migration, invasion, and induced apoptosis. The radiomics model achieved an AUC of 0.931 in the training set and 0.760 in the validation set for predicting CR gene expression. Importantly, in the clinical validation cohort, patients with low radiomics scores had significantly longer survival (P = 0.039). Circadian rhythm-related gene expression, implicated in HCC development, can be non-invasively predicted via CT-based radiomics. The proposed model offers promise for prognostic stratification and personalized treatment planning in HCC.
- 18 August 2025
- Published by Elsevier in Carbohydrate Polymers
- Vol. 369, 124244
A versatile chitosan hydrogel crosslinked by boronated diol drug conjugates as anti-tumor immune stimulator for hepatocellular carcinoma treatment
- 18 August 2025
- Published by Elsevier in Carbohydrate Polymers
- Vol. 369, 124244
A versatile chitosan hydrogel crosslinked by boronated diol drug conjugates as anti-tumor immune stimulator for hepatocellular carcinoma treatment
- 1 August 2025
- Published by Bentham Science Publishers Ltd. in Combinatorial Chemistry & High Throughput Screening
- Vol. 28 (13) , 2263-2278
ZFC3H1 as an Indicator of Poor Prognosis in Hepatocellular Carcinoma: Bioinformatic Analysis and Experimental Verification
Background: Zinc finger C3H1-type containing (ZFC3H1) might regulate RNA processes. However, research lacks the prognostic value of ZFC3H1 in hepatocellular carcinoma (HCC). Methods: The study analyzed ZFC3H1 expression in HCC cells and its correlation with patient prognosis using transcriptomics, immunohistochemistry, and quantitative real-time reverse transcription PCR, as well as single-cell RNA expression data. Additionally, Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses were used to investigate the potential ZFC3H1-related cellular functions and signaling pathways. The impact of ZFC3H1 expression on the tumor microenvironment and tumor mutational burden (TMB) was assessed using the ESTIMATE algorithm. Cell-based assays, including cell counting kit 8, proliferation, colony formation, cell cycle, wound healing, and Transwell assays, were conducted to evaluate the influence of ZFC3H1 on hepatocellular carcinoma proliferation and migration. Results: ZFC3H1 is upregulated in HCC and linked to tumor progression. High ZFC3H1 expression is a prognostic risk factor for HCC, according to Kaplan-Meier and Cox regression analyses. ESTIMATE analysis suggested that ZFC3H1 reduces immune cell infiltration and increases the TMB. Patients with low ZFC3H1 expression might respond better to immunotherapy. High ZFC3H1 expression is associated with increased half-maximal inhibitory concentration (IC50) of sorafenib. Functional experiments demonstrated that reducing ZFC3H1 expression inhibited HCC cell proliferation and migration. Conclusion: ZFC3H1 is upregulated in HCC, promoting the proliferation and migration of liver cancer cells, impacting the prognosis of HCC patients and the effectiveness of immunotherapy. ZFC3H1 might serve as a therapeutic target and biomarker for HCC.
- 1 August 2025
- Published by Bentham Science Publishers Ltd. in Combinatorial Chemistry & High Throughput Screening
- Vol. 28 (13) , 2263-2278
ZFC3H1 as an Indicator of Poor Prognosis in Hepatocellular Carcinoma: Bioinformatic Analysis and Experimental Verification
Background: Zinc finger C3H1-type containing (ZFC3H1) might regulate RNA processes. However, research lacks the prognostic value of ZFC3H1 in hepatocellular carcinoma (HCC). Methods: The study analyzed ZFC3H1 expression in HCC cells and its correlation with patient prognosis using transcriptomics, immunohistochemistry, and quantitative real-time reverse transcription PCR, as well as single-cell RNA expression data. Additionally, Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses were used to investigate the potential ZFC3H1-related cellular functions and signaling pathways. The impact of ZFC3H1 expression on the tumor microenvironment and tumor mutational burden (TMB) was assessed using the ESTIMATE algorithm. Cell-based assays, including cell counting kit 8, proliferation, colony formation, cell cycle, wound healing, and Transwell assays, were conducted to evaluate the influence of ZFC3H1 on hepatocellular carcinoma proliferation and migration. Results: ZFC3H1 is upregulated in HCC and linked to tumor progression. High ZFC3H1 expression is a prognostic risk factor for HCC, according to Kaplan-Meier and Cox regression analyses. ESTIMATE analysis suggested that ZFC3H1 reduces immune cell infiltration and increases the TMB. Patients with low ZFC3H1 expression might respond better to immunotherapy. High ZFC3H1 expression is associated with increased half-maximal inhibitory concentration (IC50) of sorafenib. Functional experiments demonstrated that reducing ZFC3H1 expression inhibited HCC cell proliferation and migration. Conclusion: ZFC3H1 is upregulated in HCC, promoting the proliferation and migration of liver cancer cells, impacting the prognosis of HCC patients and the effectiveness of immunotherapy. ZFC3H1 might serve as a therapeutic target and biomarker for HCC.
- 22 April 2025
- Published by Elsevier in Journal of Surgical Research
- Vol. 309, 199-211
The Association of Age and Liver Transplant Outcomes in Patients With Acute-On-Chronic Liver Failure
- 22 April 2025
- Published by Elsevier in Journal of Surgical Research
- Vol. 309, 199-211
The Association of Age and Liver Transplant Outcomes in Patients With Acute-On-Chronic Liver Failure
- Open Access
- 12 March 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 16 (1) , 1-12
The effect of TIM1+ Breg cells in liver ischemia-reperfusion injury
Liver transplantation is the only effective method for end-stage liver disease; however, liver ischemia reperfusion injury (IRI) seriously affects donor liver function after liver transplantation. IRI is a pathophysiological process in which organ damage is aggravated after the blood flow and oxygen supply of ischemic organ tissues are restored. It combines the two stages of hypoxic cell stress triggered by ischemia and inflammation-mediated reperfusion injury. Herein, we studied the protective effect and mechanism of the anti-T cell Ig and mucin domain (TIM1) monoclonal antibody, RMT1-10, on hepatic cell injury induced by IRI. First, a liver IRI model was established in vivo. HE, TEM, and Tunel were used to detect liver tissue injury, changes in the liver ultrastructure and liver cell apoptosis, respectively. ELISA were performed to determine the levels of ALT, AST, MDA, GSH, and related inflammatory factors. We found that RMT1-10 could significantly reduce liver injury. Flow cytometry results showed that the number of TIM1+ regulatory B cells (Bregs) in the IRI liver increased briefly, while pretreatment with RMT1-10 could increase the number of TIM1+ Bregs and interleukin-10 (IL-10) secretion in liver IRI model mice, thus playing a protective role in liver reperfusion. When Anti-CD20 was used to remove B cells, RMT1-10 had a reduced effect on liver IRI. Previous data showed that the number of T helper 1 cells (Th1:CD4+; CD8+) increased significantly after IRI. RMT1-10 inhibited Th1 cells; however, it significantly activated regulatory T cells. Sequencing analysis showed that RMT1-10 could significantly downregulate the expression of nuclear factor-kappa B (NF-κB) pathway-related genes induced by IRI. These results suggested that RMT1-10 could promote the maturation of B cells through an atypical NF-κB pathway, thereby increasing the number of TIM1+ Bregs and associated IL-10 secretion to regulate the inflammatory response, thereby protecting against liver IRI.
- 12 March 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 16 (1) , 1-12
Open AccessThe effect of TIM1+ Breg cells in liver ischemia-reperfusion injury
Liver transplantation is the only effective method for end-stage liver disease; however, liver ischemia reperfusion injury (IRI) seriously affects donor liver function after liver transplantation. IRI is a pathophysiological process in which organ damage is aggravated after the blood flow and oxygen supply of ischemic organ tissues are restored. It combines the two stages of hypoxic cell stress triggered by ischemia and inflammation-mediated reperfusion injury. Herein, we studied the protective effect and mechanism of the anti-T cell Ig and mucin domain (TIM1) monoclonal antibody, RMT1-10, on hepatic cell injury induced by IRI. First, a liver IRI model was established in vivo. HE, TEM, and Tunel were used to detect liver tissue injury, changes in the liver ultrastructure and liver cell apoptosis, respectively. ELISA were performed to determine the levels of ALT, AST, MDA, GSH, and related inflammatory factors. We found that RMT1-10 could significantly reduce liver injury. Flow cytometry results showed that the number of TIM1+ regulatory B cells (Bregs) in the IRI liver increased briefly, while pretreatment with RMT1-10 could increase the number of TIM1+ Bregs and interleukin-10 (IL-10) secretion in liver IRI model mice, thus playing a protective role in liver reperfusion. When Anti-CD20 was used to remove B cells, RMT1-10 had a reduced effect on liver IRI. Previous data showed that the number of T helper 1 cells (Th1:CD4+; CD8+) increased significantly after IRI. RMT1-10 inhibited Th1 cells; however, it significantly activated regulatory T cells. Sequencing analysis showed that RMT1-10 could significantly downregulate the expression of nuclear factor-kappa B (NF-κB) pathway-related genes induced by IRI. These results suggested that RMT1-10 could promote the maturation of B cells through an atypical NF-κB pathway, thereby increasing the number of TIM1+ Bregs and associated IL-10 secretion to regulate the inflammatory response, thereby protecting against liver IRI.
- Open Access
- 18 October 2024
- Published by Elsevier in Annals of Hepatology
- Vol. 30 (2) , 101579
Biological aging accelerates hepatic fibrosis: Insights from the NHANES 2017–2020 and genome-wide association study analysis
- 18 October 2024
- Published by Elsevier in Annals of Hepatology
- Vol. 30 (2) , 101579
Open AccessBiological aging accelerates hepatic fibrosis: Insights from the NHANES 2017–2020 and genome-wide association study analysis